|
|
|
|
| LEADER |
03549nmm a2200313 u 4500 |
| 001 |
EB001034718 |
| 003 |
EBX01000000000000000828234 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
150702 ||| eng |
| 020 |
|
|
|a 9783319173504
|
| 100 |
1 |
|
|a Anantharamaiah, G.M.
|e [editor]
|
| 245 |
0 |
0 |
|a Apolipoprotein Mimetics in the Management of Human Disease
|h Elektronische Ressource
|c edited by G.M. Anantharamaiah, Dennis Goldberg
|
| 250 |
|
|
|a 1st ed. 2015
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2015, 2015
|
| 300 |
|
|
|a XXI, 182 p. 42 illus., 22 illus. in color
|b online resource
|
| 505 |
0 |
|
|a 1. HDL and the Amphipathic Helix -- 2. ApoA-I mimetic peptides: A review of the present status -- 3. Apolipoprotein Mimetic Peptides for Stimulating Cholesterol Efflux -- 4. ApoA-I Mimetic Peptides and Diabetes -- 5. Apolipoprotein A-I mimetic peptides in Mouse Models of Cancer -- 6. Effects of ApoA-I mimetic peptide L-4F in LPS-mediated inflammation -- 7. Apolipoprotein mimetics in the amelioration of respiratory inflammation -- 8. Regulation of Macrophage Polarity by HDL, Apolipoproteins And Apolipoprotein Mimetic Peptides -- 9. Apolipoprotein E & Atherosclerosis: Beyond Lipid Effects -- 10. Apolipoprotein E mimetic peptides – Cholesterol dependent and independent properties -- 11. Apolipoprotein-E and Mimetics as Targets and Therapeutics for Alzheimer’s Disease
|
| 653 |
|
|
|a Medicine/Public Health, general
|
| 653 |
|
|
|a Cardiology
|
| 653 |
|
|
|a Medical biochemistry
|
| 653 |
|
|
|a Medical Biochemistry
|
| 653 |
|
|
|a Cardiology
|
| 653 |
|
|
|a Medicine
|
| 700 |
1 |
|
|a Goldberg, Dennis
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-17350-4?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 612.015
|
| 520 |
|
|
|a This comprehensive book provides not only the stages in the development of this unique and specialized field but also updates on the current state of research and development of apolipoprotein mimetics as therapeutic modalities for various lipid-mediated disorders. The book consists of 11 chapters all written by leading scientists from well-reputed laboratories in the USA. After an introduction by Dr. Godfrey Getz, Professor of Medicine at the University of Chicago and the Associate Editor of the Journal Lipid Research, the book presents a narration of how a theory can lead to the discovery of treatment modalities to several devastating diseases such as diabetes, Alzheimer’s disease, arthritis; asthma; atherosclerosis, chronic rejection of transplanted hearts and cancer. Present therapies for most of these diseases are not adequate. Using the models of two long anti-atherogenic and anti-inflammatory proteins (apolipoprotein A-I and apolipoprotein E with 243 and 299 amino acids, respectively) short mimetic peptides of 18 to 28 amino acid residues in length, which can be produced either synthetically or genetically in edible fruits and vegetables, have been shown to exert profound biological effects in a large number of animal models of diseases. The book also presents novel ideas, highly unexpected mechanisms of action in animal models and even in initial clinical studies in humans, which can lead to additional improvements in basic and clinical research in biological science. All the chapters are written by experts in their respective fields who have contributed immensely to the literature. This is the first compendium of this growing field presented in the form of a book
|